View Cart  

Teva’s Orphan Leukemia Drug Lands Accelerated Approval

A A
Teva plans to launch its orphan chronic myeloid leukemia (CML) drug Synribo by mid-November after getting accelerated approval Oct. 26.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00